Generalized Anxiety Disorder (GAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Generalized Anxiety Disorder (GAD) Market Outlook

Thelansis’s “Generalized Anxiety Disorder (GAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Anxiety Disorder (GAD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Generalized Anxiety Disorder (GAD) Overview

Generalized anxiety disorder (GAD) is a mental health condition characterized by persistent feelings of fear, worry, and being overwhelmed. It involves excessive and unrealistic concerns about daily matters, possibly stemming from various factors such as stress, underlying medical conditions like diabetes, co-existing conditions like depression, genetic predisposition (with about a 25% likelihood among first-degree relatives), and environmental influences like childhood trauma or substance abuse. While the exact cause remains unclear, research suggests the involvement of neurotransmitter systems like noradrenaline and serotonin in the body's stress response, with low serotonin activity and heightened noradrenergic activity potentially contributing to its development. Normal anxiety can manifest in children, typically starting with stranger anxiety around seven to nine months of age. Diagnosis of GAD may involve thyroid function tests, blood glucose monitoring, echocardiography, and toxicology screening. Treatment options primarily revolve around cognitive behavioral therapy and medications, with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) being preferred due to their ability to modulate these neurotransmitter systems. Response rates to these medications typically range from 30% to 50%. XANAX (1981) is the approved product for the treatment of Generalized anxiety disorder (GAD).

• Generalized Anxiety Disorder (GAD) impacts 6.8 million adults, constituting 3.1% of the U.S. population. However, only 43.2% of affected individuals are undergoing treatment.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: